

October 10, 2025

2026 Update in Care of the Hematologic Malignancies Patient: With proceedings from International Medical Meetings

A CME/CNE – Accredited Conference

Friday, January 23, 2026

7:00 am to 4:00 pm

In Person at Hilton Philadelphia City Avenue

4200 City Avenue, Philadelphia, PA 19131

On behalf of the Office of Continuing Medical and Interprofessional Education and the Abramson Cancer Center of the University of Pennsylvania, we officially invite your company to exhibit at our upcoming **2026 Update in Care of the Hematologic Malignancies Patient: With proceedings from International Medical Meetings** – CME/CNE-certified activity.

PennMedicine.org/Abramson/BloodCME2026. The meeting is scheduled to take place on Friday, January 23, 2026, 7:00 am to 4:00 pm.

The educational meeting will be separate from the exhibit hall.

The cost to exhibit is \$4000.

In Person Only Exhibit Table

- One (1) exhibit table at the venue.
- Registration for two (2) representatives to attend all conference sessions and meals in person.
- Company listing in the conference materials (printed and digital)

In-Person Exhibitor Display Information:
<ul style="list-style-type: none">• Exhibitors are responsible for supplies, set-up, takedown, delivery and any additional costs related to your display.• You will be provided with a skirted table and access to electrical outlets.

Provider Background

In support of improving patient care, Penn Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. The CME program at Penn Medicine is administered by Office of Continuing Medical and Interprofessional Education office. The professional continuing education of physicians has always been an important part of the institution's missions in education, research and patient care.

All presentations provided as part of our certified educational activities are peer-reviewed to ensure that all content is valid, unbiased, scientifically sound, and that all clinical recommendations are based on the best evidence available. We aim for the highest levels of evaluations available to include measurements of outcomes at the levels that go beyond capturing just participants' reaction and whether the learning occurred, and concentrate on behavioral changes and achievement of results that will result in patient care improvements.

Overview

This course is a comprehensive review of hematologic malignancies focusing on research developments over the preceding year and their application to the patient care journey. Didactic presentations will include case discussion with Penn faculty and community experts. Activity format will provide significant opportunity for interaction with expert faculty and other attendees with the aim of implementing new standards of patient care. Participants will leave with up-to-date, practical information which will have immediate clinical application.

Objectives

At the completion of this course, participants should be able to:

- Identify clinical features, including differential diagnoses for the various hematologic malignancies
- Identify late effects and survivorship issues following cellular therapy
- Implement strategies that incorporate state-of-the-art genomic analyses for hematologic malignancies
- Identify new data for Hereditary Myeloid Disorders
- Select appropriate hematologic malignancy patients for immunotherapy
- Select appropriate clinical trials for hematologic malignancies
- Identify the major patient management issues experienced by the Interprofessional care team associated with hematologic malignancies
- Apply new strategies for incorporating therapies that target metabolism in blood cancers

Who Should Attend

This activity is designed for hematologists, medical and radiation oncologists, primary care physicians, pathologists, hematology/oncology fellows, oncology nurses, oncology social workers, and other healthcare professionals involved in the treatment of patients with blood cancer.

It is expected that 550 will attend.

If you are interested in exhibiting, please visit the [Exhibitor Tab](#) where you will find:

- Exhibitor Agreement
- Letter of Request
- Agenda

Once you complete the [Exhibitor Agreement](#), you will receive instructions on how to pay electronically, via web or by check via US mail.